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Abstract: Chronic obstructive pulmonary disease (COPD) is associated with major health-
care and socioeconomic burdens. International consortia recommend a personalized approach 
to treatment and management that aims to reduce both symptom burden and the risk of 
exacerbations. Recent clinical trials have investigated single-inhaler triple therapy (SITT) 
with a long-acting muscarinic antagonist (LAMA), long-acting β2-agonist (LABA), and 
inhaled corticosteroid (ICS) for patients with symptomatic COPD. Here, we review evidence 
from randomized controlled trials showing the benefits of SITT and weigh these against the 
reported risk of pneumonia with ICS use. We highlight the challenges associated with cross- 
trial comparisons of benefit/risk, discuss blood eosinophils as a marker of ICS responsive-
ness, and summarize current treatment recommendations and the position of SITT in the 
management of COPD, including potential advantages in terms of improving patient adher-
ence. Evidence from trials of SITT versus dual therapies in symptomatic patients with 
moderate to very severe airflow limitation and increased risk of exacerbations shows benefits 
in lung function and patient-reported outcomes. Moreover, the key benefits reported with 
SITT are significant reductions in exacerbations and hospitalizations, with data also suggest-
ing reduced all-cause mortality. These benefits outweigh the ICS-class effect of higher 
incidence of study-reported pneumonia compared with LAMA/LABA. Important differences 
in trial design, baseline population characteristics, such as exacerbation history, and assess-
ment of outcomes, have significant implications for interpreting data from cross-trial com-
parisons. Current understanding interprets the blood eosinophil count as a continuum that can 
help predict response to ICS and has utility alongside other clinical factors to aid treatment 
decision-making. We conclude that treatment decisions in COPD should be guided by an 
approach that considers benefit versus risk, with early optimization of treatment essential for 
maximizing long-term benefits and patient outcomes. 
Keywords: all-cause mortality, exacerbations, hospitalizations, ICS, LABA, LAMA
Introduction
Chronic obstructive pulmonary disease (COPD), the third leading cause of death 
worldwide,1 is a major healthcare burden and a common cause of hospital admissions. 
The progressive nature of the disease is likely to impact on work productivity and, in 
many countries, this may contribute to higher rates of premature retirement and 
subsequent loss of income.2 The treatment and management of COPD also carries 
a significant economic burden,3,4 which is mainly attributed to exacerbations of COPD, 
particularly those leading to hospitalization.5–8 These have serious clinical implica-
tions, resulting in an expedited decline of lung function, decreased health-related 
quality of life, and increased risk of rehospitalization and mortality.9–11 Prevention of 
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exacerbations and hospitalizations is a major goal of treat-
ment strategies yet remains a significant unmet need.11
The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 2020 Strategy report recommends 
a personalized approach for the treatment and management 
of patients with COPD.3 The aim is to reduce both symp-
tom burden and the risk of future exacerbations. Smoking 
cessation remains the most important modifiable risk fac-
tor influencing disease progression in COPD.3 Despite 
treatment recommendations such as those in the GOLD 
report, observations from clinical practice suggest some 
divergence in prescribing.12–18 There remains much inertia 
in how physicians manage and treat COPD, with many 
primary care providers either choosing to deviate from 
guideline-indicated treatment or being unaware of these 
guidelines.19 It is unknown whether more clearly defined 
recommendations incorporating exacerbation risk and 
blood eosinophil count to guide therapy within recently 
developed frameworks will help to change this. One of the 
main challenges is to identify those patients whom opti-
mizing therapy can help drive better disease outcomes.
Initial pharmacological therapy for COPD centers on 
the use of short- and long-acting bronchodilators. 
Escalation of treatment for patients with symptomatic 
COPD and at risk of exacerbations includes combined 
therapy of long-acting bronchodilator and/or inhaled cor-
ticosteroid (ICS) containing regimens.3 The emerging clin-
ical trial data examining single-inhaler triple therapy 
(SITT) with a long-acting muscarinic antagonist 
(LAMA), long-acting β2-agonist (LABA) and ICS for 
patients with symptomatic COPD and at risk of 
exacerbations20–26 has driven further debate around opti-
mizing treatment for these patients.27–29
A recent systematic review and meta-analysis has high-
lighted the superior benefit/risk profile of triple therapy 
over dual or mono-bronchodilator therapy in patients with 
a history of exacerbations, noting that in such patients the 
reduction in exacerbations outweighs the risk of 
pneumonia.30 This article reviews evidence from rando-
mized controlled trials (RCTs) that investigated the bene-
fits of SITT for improving lung function and reducing 
symptoms, exacerbations, hospitalizations, and mortality 
in patients with COPD compared with those on dual com-
bination therapy, and weighs these against the risk of 
pneumonia associated with ICS use. We highlight the 
benefits of SITT on all-cause mortality, explore the limita-
tions of cross-trial comparisons and discuss the role of 
blood eosinophils as a marker of response to ICS. 
Finally, we summarize current treatment recommendations 
and the position of SITT in the management of COPD.
Evaluating the Benefits of SITT in 
COPD: Lessons from the Literature
There is a growing body of evidence that treatment with 
SITT improves lung function, symptoms, and health- 
related quality of life and reduces moderate and severe 
exacerbations in patients with symptomatic COPD. Here, 
we present an overview of the clinical trials examining the 
efficacy and safety of SITT in patients with COPD.
Trials with Lung Function as the Primary 
Endpoint
The TRILOGY, KRONOS and FULFIL trials had primary 
endpoints of lung function, symptoms and/or health-related 
quality of life (Table 1). Baseline patient characteristics for 
these studies are provided in Table 2. TRILOGY compared 
beclometasone dipropionate (BDP)/formoterol fumarate 
(FM)/glycopyrronium bromide (GLY) with BDP/FM over 
52 weeks in 1367 patients with symptomatic COPD (with 
a post-bronchodilator forced expiratory volume in 1 second 
[FEV1] <50%, and at least one exacerbation in the 
previous year).25 During the 2-week run-in period, patients 
received BDP/FM (Table 1).25 KRONOS was a 24-week 
trial comparing budesonide (BUD)/GLY/FM with FM/GLY, 
BUD/FM and open-label BUD/FM (delivered by dry pow-
der inhaler [DPI]) in 1896 patients with symptomatic but 
non-exacerbating COPD (74% of patients had no exacerba-
tions in the preceding year).20 Patients received ipratropium 
bromide as maintenance medication during the run-in per-
iod and the use of ICS was permitted (Table 1).20 In the 
FULFIL trial, fluticasone furoate (FF)/umeclidinium 
(UMEC)/vilanterol (VI) was compared with BUD/FM (via 
DPI) over 24 weeks in 1810 patients with symptomatic 
COPD (either with FEV1 <50% predicted, or with FEV1 
50–<80% predicted and at least two moderate or one severe 
exacerbation in the preceding year).21 Patients’ COPD 
maintenance medication was unchanged during the run-in 
period (Table 1), to more closely resemble clinical 
practice.21 A subset of patients remained on study treatment 
for up to 52 weeks.21
All three trials showed significant improvements in 
lung function with SITT versus dual therapy. In 
TRILOGY, SITT improved trough FEV1 by 63 mL at 52 
weeks (81 mL at 26 weeks) compared with ICS/LABA, in 
KRONOS a 59–74 mL improvement was seen with SITT 
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versus ICS/LABA over 24 weeks, and in FULFIL 
a 171 mL improvement at 24 weeks (179 mL at 52 
weeks; Table 1). There were generally no significant 
improvements in Transition Dyspnea Index (TDI) scores, 
except for the comparison of BUD/GLY/FM with open- 
label BUD/FM in KRONOS (Table 1). Improvements in 
health-related quality of life measured by the St George’s 
Respiratory Questionnaire (SGRQ) were seen in all trials, 
although results were not always statistically significant 
(Table 1).20,21,25 Overall, data from these three trials 
demonstrated the lung function and health-related quality 
of life benefits with SITT versus ICS/LABA dual therapy 
in patients with symptomatic COPD.
The rate of moderate or severe exacerbations was 
a defined secondary endpoint in all three trials, 
although, in keeping with the patient population 
recruited, reported annual rates of exacerbations were 
low. Both TRILOGY and FULFIL reported significant 
reductions in moderate/severe exacerbation rates with 
SITT versus ICS/LABA (Table 1).21,25 In the KRONOS 
trial, there was a significant reduction in exacerbation 
rates with BUD/GLY/FM versus FM/GLY but not ver-
sus BUD/FM or open-label BUD/FM.20 Unusually, the 
raw exacerbation rate captured in the year before study 
entry was lower than the model-estimated exacerbation 
rate observed during the trial in all treatment arms; this 
was most notable in the FM/GLY arm (0.3 before study 
entry; 0.95 model-estimated at 24 weeks), where it 
increased to more than double the rate in the 
BUD/GLY/FM arm at the end of the trial (0.4 before 
study entry; 0.46 model-estimated at 24 weeks).20 This 
observation is unexpected and these data thus need to 
be interpreted with caution.
The incidence of pneumonia was evaluated in the 
safety analyses of all three trials. It is important to note 
that inferences regarding ICS-induced pneumonia risk 
need to take into account interactions with other risk 
factors.31 For example, a recent pooled analysis of studies 
in patients with COPD treated with ICS/LABA medica-
tions indicated that the only risk factor for ICS-induced 
pneumonia was a low body mass index (<25 kg/m2).31 
Previous studies have also shown that the highest risk 
factors for pneumonia are disease severity and exacerba-
tion history (Figure 1). In the TRILOGY, KRONOS, and 
FULFIL trials, pneumonia rates were low and comparable 
with each SITT and comparator groups (Table 3). It is 
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in different ways, which limits cross-trial comparisons 
(Table 4).
Trials with Exacerbation Reduction as the 
Primary Outcome
Exacerbation rate was the primary endpoint in the 
TRIBUTE, IMPACT, and ETHOS trials (Table 1). In 
TRIBUTE, BDP/FM/GLY was compared with indacaterol 
(IND)/GLY over 52 weeks in 1532 patients with sympto-
matic COPD with severe or very severe airflow limitation 
(FEV1 <50% predicted) and at least one moderate or 
severe exacerbation in the previous year (baseline charac-
teristics for this and the other studies discussed in this 
section are provided in Table 2).23 Patients received one 
inhalation of IND/GLY per day during the run-in period 
(Table 1).23 The IMPACT trial compared FF/UMEC/VI 
with FF/VI and UMEC/VI over 52 weeks in 10,355 
patients with symptomatic COPD and at least one exacer-
bation in the previous year (55% had ≥2 moderate or 
severe exacerbations [Table 2]).22 Patients continued on 
their COPD maintenance medication during the run-in 
period (Table 1), reflecting clinical practice.22,32 The 
ETHOS trial compared BUD/GLY/FM, at two different 
doses of BUD (320 and 160 µg), with FM/GLY and 
BUD/FM over 52 weeks in 8509 patients with sympto-
matic COPD and a history of exacerbations (57% had ≥2 
moderate or severe exacerbations [Table 2]).24 Patients 
discontinued maintenance medications during the run-in 
period, and received ipratropium bromide, which may 
have contributed to almost 50% of screened patients not 
being eligible for randomization (Table 1).24
In all studies, SITT reduced moderate/severe exacerbation 
rates and improved lung function and health-related quality of 
life (as measured by SGRQ total score) compared with dual 
therapies (Table 1).22–24 In TRIBUTE, BDP/FM/GLY reduced 
the annual rate of moderate/severe exacerbations by 15% 
versus IND/GLY. The observed exacerbation rate with each 
treatment was low, reflecting the characteristics of the patients 
recruited (81% of patients had one, and only 19% two or more, 
moderate or severe exacerbations in the preceding year). 
Compared with IND/GLY, BDP/FM/GLY also significantly 
improved SGRQ (difference −1.6 units) but did not signifi-
cantly improve FEV1 at 52 weeks (difference 19 mL).23 In 
Figure 1 Disease severity and exacerbation history are strongly correlated with pneumonia risk whereas ICS only adds a small additional risk. 
Abbreviations: BMI, body mass index; CAP, community-acquired pneumonia; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; OCS, oral corticosteroid; OR, odds ratio. The graph 
has been independently created from the original data.49
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IMPACT, FF/UMEC/VI significantly reduced the annual rate 
of moderate or severe COPD exacerbations by 15% compared 
with FF/VI and by 25% compared with UMEC/VI.22 
FF/UMEC/VI also significantly improved trough FEV1 (dif-
ference 97 mL vs FF/VI, 54 mL vs UMEC/VI) and SGRQ 
(difference −1.8 units vs each dual therapy). Recently pub-
lished post hoc analyses of IMPACT show that the observed 
improvements in exacerbations, FEV1, and SGRQ with 
FF/UMEC/VI compared with UMEC/VI were not driven by 
abrupt ICS withdrawal in prior ICS users randomized to 
LAMA/LABA.32 In ETHOS, both BUD/GLY/FM arms led 
to a significant reduction in the annual rate of moderate or 
severe exacerbations (13–25% reduction; Table 1). BUD 320 
µg SITT also improved trough FEV1 compared with FM/GLY 
and BUD/FM (difference 55 and 65 mL, respectively), and 
SGRQ total score (difference −1.6 and −1.4 units, respec-
tively) (Table 1).
The incidence of pneumonia was evaluated in all three 
of these trials. Using the LAMA/LABA arm as a baseline 
in each of these studies, the results show no difference in 
pneumonia adverse event (AE) incidence in TRIBUTE 
between SITT and LAMA/LABA, a 1.6-fold difference 
in IMPACT and a 1.9-fold difference in ETHOS (for 
BUD 320 µg SITT vs LAMA/LABA) (Table 3). Data 
were similar with regards to pneumonia serious AEs, 
with a 1.1-fold difference in TRIBUTE, 1.7-fold in 
IMPACT and 2.3-fold in ETHOS (for BUD 320 µg SITT 
vs LAMA/LABA) (Table 3). ETHOS and IMPACT 
showed the clearest evidence for increased risk of pneu-
monia for ICS-containing medicines.22,24 This was most 
likely related to the severity of the patient populations and 
the size of the studies, and the relative increase in risk with 
ICS use was comparable to LAMA/LABA treatment 
arms.22,24 Cross-trial comparisons should be interpreted 
with extreme caution due to differences in trial design, 
baseline population characteristics, definitions of pneumo-
nia (adjudicated vs all reported; Table 4), and assessment 
of outcomes. This was recognized in a 2016 report from 
the European Medicines Agency (EMA)’s 
Pharmacovigilance Risk Assessment Committee (PRAC), 
which recognized pneumonia as a class effect of ICS- 
containing therapies in patients with COPD, with no con-
clusive evidence of intra-class differences.33 Similarly, 
a European public assessment report (EPAR) assessment 
report on BDP/FM/GLY published by the EMA in 
December 2018 concluded that: Differences in study 
design, methodology for confirming the diagnosis of pneu-
monia, sample size and populations assessed . . . do not 
allow drawing meaningful conclusions of whether 
Trimbow® has a more favorable benefit/risk profile . . . 
than the triple combination [FF/UMEC/VI] assessed in 
the IMPACT study.34
Head-to-Head Trials of Triple Therapy 
with Different ICS Components
While it remains very difficult to make cross-trial compar-
isons, head-to-head trials comparing different ICS- 
containing treatments in the same population help to under-
stand benefit and risk. The TRISTAR trial compared SITT 
using BDP/FM/GLY with multiple-inhaler triple therapy in 
the form of FF/VI plus tiotropium (TIO) as the comparator 
group.35 The study was conducted over 26 weeks in 1157 
patients with symptomatic COPD with severe or very severe 
airflow limitation and at least one exacerbation in the 
preceding year. Results showed that both triple therapies 
had comparable benefit and risk profiles. BDP/FM/GLY 
was non-inferior to FF/VI plus TIO for the primary endpoint 
of change from baseline in SGRQ total score at Week 26, 
with improvements of −6.77 and −7.82 units, respectively.35 
Improvements in trough FEV1 at Week 26 were greater with 
FF/VI plus TIO (109 mL) compared with BDP/FM/GLY 
(59 mL), and rates of moderate and severe exacerbations 
over the 26 weeks of treatment were low and comparable 
between the treatment arms (0.516 for BDP/FM/GLY and 
0.474 for FF/VI plus TIO).35 Similar rates of serious AEs of 
pneumonia (captured using the preferred terms of bronchop-
neumonia, lobar pneumonia, pneumonia, and pneumonia 
staphylococcal) were reported for BDP/FM/GLY (1.4%) 
and FF/VI plus TIO (1.9%).35
Two different ICS-containing treatments were also 
compared in the FULFIL trial. As discussed above, 
FF/UMEC/VI significantly improved FEV1 and SGRQ 
total score and reduced exacerbations at 24 weeks com-
pared with BUD/FM.21 The rate of pneumonia AEs of 
special interest (AESIs; defined as AEs that are pharma-
cologically related to the use of ICS, LAMA or LABA) 
was 2% with FF/UMEC/VI and 1% with BUD/FM at 24 
weeks and was 2% for both treatments at 52 weeks. Thus, 
in both FULFIL and TRISTAR, pneumonia rates were 
comparable between treatment arms.
Hospitalizations and All-Cause Mortality
Patients with COPD account for approximately one- 
quarter of all hospitalizations.36 Severe exacerbations of 
COPD leading to hospitalization are associated with 
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substantial mortality and risk of recurrence, with the risk 
of death highest after a hospitalization and increasing with 
the frequency of such events.11,37–40 Reducing exacerba-
tion-related hospitalizations is an essential treatment goal 
for many patients with COPD. Typically, clinical trials 
have focused on the incidence of moderate and severe 
exacerbations combined (data for which have already 
been described); however, trials conducted in 
a population of patients at high risk of exacerbation, such 
as TRIBUTE, IMPACT, and ETHOS, have also assessed 
severe exacerbations (events leading to hospitalization or 
death) separately.22–24 Two of these trials, IMPACT and 
ETHOS, also assessed the risk of all-cause mortality as 
a pre-specified endpoint.22,24
In TRIBUTE, there was a non-significant reduction in 
the rate of severe exacerbations with BDP/FM/GLY SITT 
compared with IND/GLY (Table 5).23 In the ETHOS trial, 
BUD 320 µg SITT significantly reduced severe exacerba-
tion rates versus BUD/FM (20% relative reduction) but not 
versus FM/GLY (16% relative reduction; P=0.09); none of 
the comparisons between BUD 160 µg SITT and dual 
therapies were statistically significant (Table 5).24 In 
IMPACT, SITT with FF/UMEC/VI significantly reduced 
the annual rate of severe exacerbations compared with 
UMEC/VI (34% relative reduction), but not FF/VI (13% 
relative reduction; P=0.06) (Table 5).22
All-cause mortality was not a pre-specified outcome in 
the TRIBUTE trial; incidence of AEs leading to death was 
2% in the BDP/FM/GLY arm and 3% in the IND/GLY 
arm.23 A post hoc pooled analysis evaluated all fatal AEs 
reported in the TRILOGY, TRINITY, and TRIBUTE 
trials.26 A non-significant trend was observed for reduced 
risk of a fatal AE in patients with severe/very severe 
COPD at increased risk for exacerbations who received 
ICS-containing versus non-ICS-containing treatments 
(29% relative risk reduction [0.71% absolute risk reduc-
tion]; P=0.066). A similar non-significant reduction in 
fatal AEs was seen for BDP/FM/GLY SITT versus non- 
ICS treatments (28% relative risk reduction [0.69% abso-
lute risk reduction]; P=0.096).26 These findings, however, 
should be interpreted with caution for several reasons: 
mortality was not a pre-specified endpoint in any of the 
studies; follow-up was incomplete; the absence of a non- 
ICS arm in TRILOGY; the majority of patients (58%) in 
the pooled comparator group received only LAMA and not 
dual therapy; and the analysis was based on the number of 
patients with AEs that led to a fatal outcome rather than on 
fatal events.
The TORCH and SUMMIT trials, both powered for the 
primary outcome of all-cause mortality, failed to show 
a statistically significant benefit on survival for 
ICS/LABA compared with placebo, despite fewer deaths 
with ICS/LABA.41,42 However, there are key differences 
in study population between these earlier studies and the 
more recent studies of SITTs that should be taken into 
consideration when evaluating the potential value of ICS 
in reducing mortality. TORCH recruited patients with 
a pre-bronchodilator FEV1 <60% predicted and post- 
bronchodilator increase in FEV1% predicted <10%, while 
SUMMIT recruited those with moderate airflow limitation 
(FEV1 50–70% predicted) and a history or increased risk 
of cardiovascular disease; in neither study was a history of 
exacerbations required, which is a major difference in the 
patients enrolled in these studies compared with the more 
recent IMPACT and ETHOS trials.
All-cause mortality was prospectively examined as 
a pre-specified endpoint in both the IMPACT and 
ETHOS trials. In IMPACT, FF/UMEC/VI significantly 
reduced the risk of all-cause on-treatment mortality by 
42% compared with UMEC/VI in patients with sympto-
matic COPD and at high risk of exacerbations (absolute 
risk reduction: 0.68%).22 The inclusion of off-treatment 
deaths showed a significant 29% reduction in the risk of 
all-cause mortality with FF/UMEC/VI (Table 5).22 These 
findings have since been confirmed in a recent post hoc 
analysis following the collection of additional vital status 
data, which provides vital status at nominal Week 52 for 
99.6% of the intent-to-treat population and identified 27 
additional off-treatment deaths.43 The data were consistent 
with the original analysis and showed a 28% reduction in 
the risk of on-/off-treatment all-cause mortality with 
FF/UMEC/VI versus UMEC/VI (P=0.042; absolute risk 
reduction 0.83%).43 This demonstrates the robustness of 
the reduction in all-cause mortality originally reported in 
IMPACT. These findings are now also supported by those 
from the ETHOS study, in which BUD 320 µg SITT 
reduced the risk of on-/off-treatment all-cause mortality 
by 46% versus FM/GLY (absolute risk reduction: 1.0%; 
Table 5). There was no reduction in all-cause mortality 
risk with BUD 160 µg SITT versus either dual-therapy 
comparator arms (Table 5). The consistency of effect on 
severe exacerbation and all-cause mortality observed in 
IMPACT with FF/UMEC/VI versus UMEC/VI was not 
seen in ETHOS, with BUD 320 µg SITT not leading to 
a statistically significant reduction in severe exacerbations 
compared with FM/GLY; it is the severe exacerbations 
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leading to hospitalization that increase the risk of 
mortality.11,40 Both IMPACT and ETHOS provide support-
ing evidence of the role of ICS in reducing all-cause 
mortality risk for patients with symptomatic COPD at 
high risk of exacerbations. The absolute risk reductions, 
while apparently small, are similar to, or better than, those 
seen in studies of smoking cessation or cardioprotective 
treatments (Figure 2).44–48
Benefit versus Risk with SITT
In 2016, the EMA directed the PRAC to evaluate the 
benefit/risk balance of ICS-containing medicinal products 
for the treatment of patients with COPD. The PRAC con-
cluded that while patients with COPD treated with ICS are 
at increased risk of pneumonia (an established risk asso-
ciated with ICS use) the benefits of ICS continue to out-
weigh their risk.33 Furthermore, there was no conclusive 
evidence of differences in this risk for different ICS- 
containing products (BDP, BUD, FF, FP or flunisolide).
Exacerbation history is one of the significant driving 
factors for pneumonia risk (Figure 1),49 and this may be 
a factor in the differential incidences of pneumonia 
observed in the TRILOGY, KRONOS, FULFIL, 
TRIBUTE, ETHOS, and IMPACT trials.20–25 Principal 
eligibility criteria in these studies (Table 1) were largely 
similar: patients were 40 years or older, current or former 
smokers and had symptomatic COPD (COPD Assessment 
Test [CAT] score ≥10).20–25 However, there were substan-
tial differences in the exacerbation history of patients. At 
baseline, 74% of patients randomized in KRONOS and 
35% in FULFIL had no exacerbations in the 
preceding year (Table 2). In contrast, enrollment criteria 
meant that <1% of the study population in both ETHOS 
and IMPACT had no exacerbations in the preceding year 
(43% and 45% had one, and 57% and 55% had ≥2 exacer-
bations, respectively; Table 2). In TRIBUTE, 81% of 
patients had experienced one exacerbation in the 
preceding year, with 19% experiencing ≥2 exacerbations 
(Table 2).
There were also differences in other characteristics at 
baseline, such as patients’ prior receipt of ICS-containing 
triple therapy and lung function status (FEV1% predicted) 
(Table 2). It is worth noting that some of these differences 
relate to patients' characteristics that may influence the risk 
of pneumonia events.31 Other notable differences between 
the studies included the definition and assessment methods 
used to capture AEs such as pneumonia (Table 4). The 
absolute rate of pneumonia thus differs between study 
Figure 2 All-cause mortality benefits with SITT are similar to, or better than, smoking cessation and cardioprotective treatments. aPooled analysis of AEs leading to a fatal 
outcome (safety population); bon- and off-treatment deaths in post hoc analysis with additional vital status follow-up (vital status available for 99.6% of patients at nominal 
Week 52); canalysis included all observed data regardless of whether patients continued to receive their assigned treatment. 
Abbreviations: BDP, beclometasone dipropionate; BUD, budesonide; FF, fluticasone furoate: FM, formoterol; GLY, glycopyrronium; ICS, inhaled corticosteroid; IND, 
indacaterol; SITT, single-inhaler triple therapy; UMEC, umeclidinium; VI, vilanterol. The graph has been independently created from the original data.
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populations and definition criteria used (including the use 
or not of independent adjudication) but, in general, ICS 
approximately doubles the risk of pneumonia compared 
with non-ICS-containing regimens, as evidenced in multi-
ple studies of SITT22,24,50 and ICS/LABA.41,42,51–57 
Overall, baseline characteristics of patient populations are 
a key consideration for discussions about both efficacy and 
safety to aid clinicians in their treatment decision-making.
Tighter monitoring of the collection of safety data and 
differences in the definitions, method of assessment and 
independent adjudication of events, such as pneumonia, 
may influence the safety profile reported in different stu-
dies. The use in trials of broader definitions of pneumonia 
that do not rely on independent adjudication is more 
representative of routine clinical practice. Even so, pneu-
monia is a heterogenous event with considerable clinical 
overlap with COPD exacerbations.58 Differentiating 
between these two events poses significant 
challenges.58–61 Both hospitalization due to severe 
exacerbations and pneumonia have a profound impact 
on patient outcomes, supporting the idea that clinical 
trials should evaluate these events together as 
a composite outcome of hospitalized respiratory events, 
as recently reported for the IMPACT trial.62 In that trial, 
triple therapy with FF/UMEC/VI resulted in a significant 
17% reduction in the risk of a severe exacerbation or 
hospitalized pneumonia compared with UMEC/VI 
(P=0.011).62 Ultimately, the key is to identify patients 
with COPD who will have a favorable benefit/risk ratio 
with triple therapy.
ICS Responsiveness and Eosinophils
Identifying which patients are most likely to respond to 
ICS (and other treatments) is important to maximize the 
benefit/risk ratio and move toward a personalized medi-
cine approach for COPD.63 A recent post hoc analysis of 
three RCTs reported that only smoking history and blood 
eosinophil count were independent predictors of response 
to ICS (BUD/FM vs FM) in patients with severe or very 
severe COPD and a history of exacerbations.63 This ana-
lysis showed that the relationship between blood eosino-
phil count and likely response to ICS is a continuum and 
not dichotomous.63 An analysis of data from the IMPACT 
trial also modelled the relationship between blood eosino-
phil count as a continuous variable and ICS effects.64 
Consistent with previous findings,63 this analysis of 
IMPACT showed that the response to ICS-containing 
therapy was modulated by both blood eosinophil count 
and smoking status.64 The benefits of ICS-containing 
treatments in terms of reduction in rates of moderate/ 
severe and severe exacerbations increased with increasing 
blood eosinophil counts.64 This was seen for both 
FF/UMEC/VI and FF/VI compared with UMEC/VI,64 
indicating that the relationship between blood eosinophil 
count and exacerbation reduction is independent of back-
ground bronchodilation. This relationship was modulated 
by smoking status, with greater benefits seen in former 
versus current smokers at all blood eosinophil counts.64 
This post hoc analysis emphasizes the importance of 
smoking cessation, with the observation that current smo-
kers with lower blood eosinophil count (<200 cells/μL) 
showed no benefit of SITT over LAMA/LABA, while 
benefits were seen across the blood eosinophil continuum 
in former smokers.64
The GOLD 2020 Report now includes therapeutic 
recommendations for blood eosinophil counts and advises 
that thresholds of <100 cells/µL and ≥300 cells/µL can be 
used to identify patients with a low likelihood and the 
greatest likelihood of benefiting from ICS-containing 
therapies, respectively.3 However, recent analyses high-
light that blood eosinophil count should be viewed as 
a continuum and evaluated in the context of other risk 
factors for exacerbations, and cut-offs should not be 
regarded as explicit.63–65
It is important to note that these eosinophil data are 
from large studies and reported at mean treatment group 
level, and the implications of population-based findings at 
the individual patient level remain to be established.
Implications for Patient 
Management
Current GOLD treatment recommendations advocate 
approaches to the treatment and management of COPD 
that aim to reduce symptom burden and risk of future 
exacerbations.3 Following a review of a patient’s response 
to treatment initiation, adjustments in pharmacological 
treatment may be needed. After checking inhaler technique 
and compliance, treatment can be escalated/de-escalated 
based on the presence of the predominant symptoms of 
breathlessness and exercise limitation, and the continued 
occurrence of exacerbations whilst on maintenance ther-
apy. Any change in treatment should always be undertaken 
under close medical supervision and considering whether 
there is a lack of clinical benefit and/or presence of side 
effects. Patients with COPD and their doctors should be 
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alert for signs and symptoms of pneumonia, bearing in 
mind that the clinical features of pneumonia overlap with 
those of exacerbations of the underlying disease.33 This 
fact necessitates a more detailed exploration of the overlap 
of hospitalized respiratory events in future COPD trials.
Studies indicate that most patients with COPD would 
benefit from optimal bronchodilation with a combination of 
a LAMA and a LABA. Dual LAMA/LABA therapy has 
demonstrated improvements in patient outcomes compared 
with either agent used alone, including in symptomatic 
patients at low exacerbation risk not using concurrent ICS 
and those naïve to COPD maintenance therapy.66–79 For 
patients with high risk of exacerbations and those who remain 
symptomatic despite treatment with LAMA/LABA combina-
tion therapy, the additional use of ICS should be considered, 
informed by the use of biomarkers such as blood eosinophils 
in conjunction with other clinical factors. As COPD is 
a progressive disease, ICS withdrawal should only be consid-
ered if there are adverse effects that seem to outweigh potential 
benefits, with particular caution in patients with blood eosino-
phil counts ≥300 cells/µL, who are at greatest risk of experi-
encing a relapse of exacerbations.3
Inappropriate prescribing of triple therapy, or, in some 
cases, lack thereof when clinically indicated,18 may in part 
be due to confusion among healthcare professionals given 
the increasing number of medications, combinations, and 
inhaler devices available.80
Severe exacerbations resulting in hospitalization are key 
events for patients, with profound clinical implications. 
These include accelerated lung function decline, worsening 
of health-related quality of life, increased comorbidities, and 
significantly increased mortality.9–11 Estimates suggest 
a survival rate of less than 50% at 5 years after hospitalization 
from a severe exacerbation.38 The importance of preventing 
exacerbation-related hospitalizations and mortality should 
therefore be at the forefront of treatment and management 
strategies and, from recent evidence, SITT has a key role in 
these strategies and for improving overall patient outcomes. 
As a key driver of COPD-related healthcare costs, reducing 
severe exacerbations is also essential for reducing the sub-
stantial socioeconomic burden associated with COPD.6,11,81 
More studies in the usual care setting are required to better 
document the benefits and potential harms of therapy in the 
wider COPD population and to determine whether patients in 
routine practice are achieving expected outcomes.
In the appropriate patients, SITT also has a potential 
role to play in terms of simplifying treatment regimens, 
thereby potentially improving treatment adherence and 
patient outcomes. Until recently, triple therapy required 
the use of multiple inhalers, sometimes several times 
per day.80 Compared with single-inhaler use, the use of 
multiple inhalers has been shown to be associated with 
poorer persistence and adherence to COPD medication, 
which could, in turn, lead to poor symptom control, higher 
healthcare utilization and costs, and reductions in health- 
related quality of life.82–85 The randomized, Phase IV 
effectiveness INTREPID study (NCT03467425) provides 
supporting evidence for the benefits of single- versus mul-
tiple-inhaler triple therapy.86 The study evaluated SITT 
with FF/UMEC/VI versus multiple-inhaler triple therapy 
as a class over 24 weeks, in 3092 patients with sympto-
matic COPD and a history of exacerbations who were 
already receiving triple therapy or had a documented clin-
ical indication for escalation from dual to triple therapy.86 
This study showed that, in usual clinical care, SITT with 
FF/UMEC/VI resulted in a significantly greater proportion 
of patients achieving clinically relevant health status 
improvements, and significantly improved lung function 
(in a subset of the overall population), compared with 
multiple-inhaler triple therapy, with a similar safety pro-
file, including the incidence of pneumonia serious AEs.86
Conclusions
Current evidence from recent RCTs of SITT compared 
with ICS/LABA and LAMA/LABA dual therapies con-
firms the benefits of SITT for symptomatic patients at high 
risk of exacerbations. The key benefits of SITT are sig-
nificant reductions in exacerbations and hospitalizations, 
with encouraging data suggesting a reduction in all-cause 
mortality, which should be weighed against a higher inci-
dence of study-reported pneumonia with ICS-containing 
treatment regimens. Beyond the benefits of reducing 
exacerbations, there are improvements in lung function 
and patient-reported outcomes. Treatment of COPD should 
follow an approach that weighs benefit versus risk at the 
individual patient level. Optimizing and simplifying treat-
ment as early as possible in the course of the disease to 
prevent exacerbations, and their complications, and 
improve quality of life and adherence is critical for max-
imizing long-term benefits and patient outcomes. Avoiding 
therapies that are unlikely to be of benefit to an individual 
is also essential. Identifying and using the right treatment, 
for the right patient, at the right time should underpin the 
treatment and management of patients with COPD. If this 
is done, it will lead to better outcomes for patients.
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